Safety and Effectiveness of the Akura Thrombectomy System in the Treatment of Acute Pulmonary Embolism

A

Akura Medical

Status

Begins enrollment in 1 month

Conditions

Pulmonary Embolism Acute

Treatments

Device: ATC System

Study type

Interventional

Funder types

Industry

Identifiers

NCT06362928
CP-60005

Details and patient eligibility

About

This study is a prospective, single-arm, non-randomized, interventional, multicenter feasibility study to evaluate the safety and effectiveness of percutaneous mechanical thrombectomy using the Akura Thrombectomy System in subjects with acute pulmonary embolism (PE).

Enrollment

15 estimated patients

Sex

All

Ages

18 to 90 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patient is > 18 and < 90 years old
  • Clinical signs and symptoms consistent with acute PE
  • PE symptom duration ≤ 14 days
  • CTA evidence of proximal PE (filling defect in at least one main or lobar pulmonary artery as determined by the investigator)
  • CTA evidence of RV/LV ratio > 0.9 note: based on Investigator's interpretation of RV/LV ratio at baseline;
  • Systolic BP ≥ 90 mmHg note: initial SBP may be < 90 mmHg but ≥ 80 mmHg if the pressure recovers with volume resuscitation
  • Stable heart rate (HR) < 130 BPM prior to procedure
  • Patient is deemed medically eligible for interventional procedure(s), per investigator guidelines and clinical judgment.
  • Subject or legally authorized representative (LAR) is willing and able to provide written informed consent prior to receiving any non-standard of care protocol specific procedures

Exclusion criteria

  • Prior PE < 180 days from index procedure
  • Thrombolytic use < 48 hours prior to baseline CTA
  • Pulmonary hypertension with peak pulmonary artery systolic pressure (PASP) >70 mmHg by right heart catheterization
  • Vasopressor requirement after fluids to keep pressure at ≥90 mmHg
  • FiO2 requirement >40% or >6 LPM to keep oxygen saturation >90%
  • Hematocrit <28% (Note: hematocrit required within 6 hrs. of index procedure)
  • Platelets count <100,000/µL
  • eGFR <30 ml/min per 1.73 m2
  • International normalized ratio (INR) >3
  • Major trauma injury severity score (ISS) > 15
  • Presence of intracardiac lead in right ventricle or atrium placed within 6 months prior to screening assessment
  • Cardiovascular or pulmonary surgery within 7 days of index procedure
  • Actively progressing cancer treated by chemotherapeutics
  • Known bleeding diathesis or coagulation disorder
  • Left bundle branch block
  • History of severe or chronic pulmonary arterial hypertension
  • History of chronic left heart disease with left ventricular ejection fraction ≤ 30%
  • History of decompensated heart failure
  • History of underlying lung disease that is oxygen dependent
  • History of chest irradiation
  • History of heparin-induced thrombocytopenia (HIT)
  • Contraindication to systemic or therapeutic doses of anticoagulants
  • Known anaphylactic reaction to radiographic contrast agents that cannot be pretreated
  • Known residual iliac deep vein thrombosis (DVT), inferior vena cava (IVC) clot or clot in transit (right atrium and/or right ventricle).
  • CTA imaging or other evidence that suggest, in the opinion of the investigator, the Subject is not appropriate for aspiration thrombectomy intervention (e.g., inability to navigate to target location, predominantly chronic clot or non-clot embolus)
  • Life expectancy <90 days, as determined by investigator
  • Female who is pregnant or nursing
  • Current participation in another investigational drug or device treatment study Note: observational or registry studies may be permitted with Sponsor approval

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

15 participants in 1 patient group

Patients with Acute Pulmonary Embolism
Experimental group
Description:
Patients undergoing mechanical thrombectomy for acute pulmonary embolism.
Treatment:
Device: ATC System

Trial contacts and locations

0

Loading...

Central trial contact

Bryan Wylie; Uday Illindala

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems